Fuji Pharma signs agreement to receive an exclusive supply of the ustekinumab biosimilar for the Japanese market, furthering a previous investment agreement.
The industry focuses investments where there is the highest potential returns, but one panel at BIO-Europe Spring suggested multiple partners could boost outcomes in underserved therapeutic areas.
Regeneron and Alnylam sign discovery agreement that could advance 30 targets within CNS and ocular disorders, during an initial five-year discovery period.
As we enter spring, several companies have refreshed the look of their executive boards – some to strengthen their direction and some out of necessity.
Cell One Partners formally launches its consulting services and aims to be a long-term partner to its clients, supporting the development of cell and gene therapies – a market which raised more than $13.3bn in 2018.
The difficulties in the manufacture of CAR-T treatments have become increasingly understood as the breakthrough technology has been commercialised, but Kite’s head of medical affairs says its process is nearly flawless.
